S&P 500
7,585.73
−0.45% Tue
Executive dashboard
Nasdaq Comp.
25,981.57
−0.78% Tue
Dow
52,093.11
−0.63% Tue
Russell 2000
2,870.29
−0.76% Tue
VIX
17.20
+0.58% Tue
U.S. 2Y
4.646%
Fed-sensitive
U.S. 10Y
4.979%
−~2 bp overnight
Dollar index
99.57
−0.08% daily bar
WTI
$104.60
−1.16% daily bar
Gold
$4,368.40
+0.82% daily bar
S&P future
7,673.75
CNBC +0.22%
Nasdaq future
29,356.50
CNBC +0.30%
| Region / index | Level | Move | Status at cutoff |
|---|---|---|---|
| Nikkei 225 | 63,822.38 | +0.53% | Wednesday close/snapshot at 15:17 JST. CNBC |
| Hang Seng | 24,688.46 | +0.09% | Live 14:17 HKT; not final. CNBC |
| Shanghai Composite | 3,889.71 | +0.66% | Live 14:17 CST; not final. CNBC |
| Euro Stoxx 50 | 6,236.50 | −0.38% | Sep. 15 close; Wednesday cash pre-open. Yahoo |
| DAX | 25,402.28 | −0.15% | Sep. 15 close; Wednesday cash pre-open. Yahoo |
| FTSE 100 | 10,658.10 | −0.37% | Sep. 15 close; UK CPI released before open. Yahoo |
| CAC 40 | 8,090.28 | −0.34% | Sep. 15 close; Wednesday cash pre-open. Yahoo |
Fed decision eclipses the overnight bounce
Futures edged up, but CME pricing cited by CNBC put a 25 bp hike at 92%; the larger risk is the dots, press conference and whether this starts a hiking sequence. Current target range is 3.50%–3.75%. CNBC · Fed
Oil eased, not normalized
WTI retreated near $104.6 after API-reported U.S. crude inventories rose 7.1M barrels versus an expected 1.6M draw, but the closed Saudi East–West pipeline keeps supply-tail risk alive. Tuesday's WTI settlement was $105.83, +4.4%. CNBC live blog
Tuesday added a second risk-off cash session
Broad U.S. indices fell again; ORCL broke the prior report's $141 confirmation level, VRT made another closing low and biotech weakened. Futures are a tentative rebound—not repaired cash breadth. CNBC markets · ORCL history
Market drivers
Macro, rates and central banks
- Fed today: decision/SEP 14:00 ET and press conference 14:30 ET (20:00/20:30 CEST). Market pricing can be wrong; policy guidance matters more than a widely expected 25 bp move. Official calendar
- Curve: official Sep. 15 Treasury fixes were 4.67% at 2Y and 5.00% at 10Y; CNBC's overnight snapshot was 4.646%/4.979%. The curve remains positively sloped, but both levels impose a high discount rate on long-duration themes. Treasury
- UK inflation: ONS released August CPI at 07:00 BST; CNBC reported headline inflation accelerated to 3.1%, driven by energy. This raises the hurdle for easing and pressures European duration before open. ONS · CNBC
- BOJ Friday: CNBC's survey had 89% expecting +25 bp to 1.25%. JGB/yen spillover can amplify global term-premium volatility. CNBC
- Still ahead: U.S. August import/export prices arrive at 08:30 ET, six hours after this report. BLS
Geopolitics, earnings, regulation and rotation
- Energy shock: Tuesday's oil surge and Wednesday's partial retracement show two-way volatility. Reported inventory builds are a near-term buffer; Saudi pipeline closure and the Iran conflict remain nonlinear risks. CNBC
- AI policy debate: semiconductor/cloud stocks stayed pressured after frontier-model leaders discussed slowing product releases for safety. This is a policy/sentiment catalyst, not evidence of cancelled hardware orders. CNBC
- Positioning counterweight: a BofA survey cited by CNBC showed a net 49% overweight global equities among 170 investors overseeing $470B; bullish positioning can support dips but also raises crowded-exit risk. CNBC
- Verified unusual move: VKTX fell 5.01% on 1.57× its prior-20-session average volume; ORCL fell 3.07% on 1.13×. Volume supports attention, not causation. VKTX · ORCL
- Filings check: SEC submissions for NVDA, VRT, COHR, IONQ, QUBT, ALT and VKTX showed no new operating filing on Sep. 15; COHR/IONQ entries were Forms 4. NVDA · IONQ
Theme dashboards
Repair attempts were narrow
- Leaders Tuesday: ANET +2.68%, AMD +2.19%, NVDA +0.57%; SMH only +0.11%.
- Laggards: ORCL −3.07%, AVGO −1.58%, VRT −1.17%. Twenty-session returns remain weak: AVGO −13.55%, VRT −19.77%, SMH −8.75%.
- Evidence: Nvidia's recent CUDA-Q Logical/QUOPS release supports ecosystem tooling, but no near-term revenue amount was disclosed. Nvidia
- Risk: 5% 10Y, energy/power scarcity, capex funding, customer concentration, exports, regulation and circular revenues can compress valuation before demand changes.
Relative strength vanished Tuesday
- Tuesday: QBTS −2.50%, QUBT −1.63%, IONQ −1.20%, RGTI −1.18%.
- 20 sessions: QBTS −21.37%, IONQ −20.90%, RGTI −19.18%, QUBT −13.37%; all tracked names remain below their 20-day averages.
- Primary information: no new operating SEC filing appeared Sep. 15 for IONQ or QUBT; IONQ filings were ownership reports. IONQ SEC · QUBT SEC
- Risk: pre-profit economics, roadmap validation, acquisitions, dilution/warrants, low commercial visibility and violent squeezes. Ecosystem progress does not prove vendor-specific advantage.
Risk-off spread to obesity names
- Tuesday: VKTX −5.01%, NVO −2.12%, ALT −2.12%, LLY −0.19%; XBI −2.27%. VKTX closed at a five-day low with above-normal volume.
- ALT Phase 2: RECLAIM's HDD/week effect was −1.45 versus placebo (p=0.0014); nausea 44% vs 24%, vomiting 18% vs 6%, drug-related discontinuation 10% vs 0%. FDA EOP2 discussion is planned, not dated. Altimmune · Registry
- VKTX catalyst: ~180-person Phase 1 maintenance trial tests weekly/every-other-week/monthly injection plus oral schedules; safety/tolerability/PK are objectives and weight durability is exploratory. Q3 data guidance remains undated. Viking
- Risk: small studies, GI safety, discontinuations, endpoint hierarchy, manufacturing, reimbursement, LLY/NVO competition, cash burn, dilution and binary gaps.
Ranked conditional ideas
Bullish list: no compelling confirmed opportunity before the FOMC. Futures are higher, but cash breadth, 5% long rates and oil above $100 do not offer a favorable evidence/risk balance. Watchlist entries require confirmation; none is a current recommendation to buy.
Bearish / short / avoid
ORCL · Oracle
Exchange/risk class: NYSE; mega-cap cloud, high capex/debt and event sensitivity. Classification: tactical bearish/avoid. Applicable horizon: day trade and 1–4 weeks; not a structural 3–12+ month short. Direction: uncertain; short loss can be unlimited.
Thesis/catalyst: Tuesday's $140.35 close (−3.07%, 1.13× volume) confirmed the prior report's break-below-$141 rule; price is below its $148.78 20-day average. Fed/rate and AI-capex scrutiny are catalysts. Evidence/counterargument: breakdown is price-confirmed, but OCI/backlog conversion or dovish Fed guidance can squeeze it.
Entry/confirmation: failed reclaim of $141–145 or a fresh break below $139 with market breadth; do not chase a gap. Invalidation/downside: bearish case weakens above $149 and invalidates on a close above $152; no target asserted. Key risks: squeeze, backlog conversion, leverage/credit, capex, power, customer concentration and Fed. Borrow availability/fees unknown. Price history · 10-Q
VRT · Vertiv
Exchange/risk class: NYSE; large-cap high-beta AI power/cooling. Classification: tactical avoid; bearish only on confirmation. Applicable horizon: day and 1–4 weeks; structural 3–12+ month demand thesis is not disproved. Direction: uncertain.
Thesis/catalyst: $234.61, −1.17%, another five-day low and −19.77% over 20 sessions; $260.63 is the 20-day average. Rates and capex-duration scrutiny remain catalysts. Evidence/counterargument: trend is damaged, but data-center power/cooling scarcity and a Fed relief rally can drive a sharp rebound.
Entry/confirmation: failed rebound into $240–245 followed by a close below $234; otherwise avoid. Invalidation/downside: close above $250 weakens, above $261 invalidates. Key risks: violent squeeze, orders, execution, input costs, valuation and Fed. Short risk unlimited; borrow terms unknown. History · SEC
VKTX · Viking Therapeutics
Exchange/risk class: Nasdaq; small-cap clinical biotech, pre-revenue, extreme binary/dilution risk. Classification: avoid until repair/data; not a short call. Applicable horizon: day and 1–4 weeks; long term only after full data. Direction: uncertain.
Thesis/catalyst: $29.95, −5.01% on 1.57× volume, broke the prior $31.39 invalidation and sits −10.94% over 20 sessions. Undated Q3 maintenance data can gap either way. Counterargument: June cash/investments were about $502M and both Phase 3 VANQUISH trials were fully enrolled; positive durability/safety could reverse price abruptly.
Entry/confirmation: no bearish entry proposed; avoid pre-data. Requalify only after acceptable safety/durability and a close above $33.31, stronger above $35. Invalidation/downside: weak durability, adverse safety/discontinuation signal, delay or financing can create an unbounded gap; the avoid stance invalidates after strong data and sustained >$35. Key risks: small exploratory study, GI effects, Phase 3 spend, FDA path, manufacturing, LLY/NVO competition and dilution. Viking
Watchlist · confirmation required
NVDA · Nvidia
Exchange/risk: Nasdaq; mega-cap semiconductor; concentration/export/valuation risk. Classification: bullish repair watch. Applicable horizon: 1–4 weeks and 3–12+ months; not an active day long. Direction: uncertain.
Thesis/catalyst/evidence: +0.57% to $212.17, but −5.71% over 20 sessions and below the $218.81 average. CUDA-Q strengthens ecosystem reach. Counterargument: SMH barely rose, 10Y remains near 5%, and capex/policy concerns persist. Entry/confirmation: hold $210.96 and close above $219 with SMH breadth; stronger above $223.67. Invalidation/downside: close below $207. Risks: customers, China/export controls, competition, supply, AI ROI and valuation. History · SEC
AMD · Advanced Micro Devices
Exchange/risk: Nasdaq; large-cap high-beta semiconductor. Classification: relative-strength watch. Applicable horizon: day and 1–4 weeks; long term requires valuation/earnings review. Direction: uncertain.
Thesis/catalyst/evidence: Tuesday +2.19% to $504.20 and above the $480.90 20-day average; best tracked AI price structure. Counterargument: still below the $521.10 five-day high; sector breadth and policy/rate backdrop are weak. Entry/confirmation: close above $521.10 with SMH expansion; pullback alternative is a successful $493 hold. Invalidation/downside: close below $480. Risks: execution, accelerator software, competition, customers, exports, supply and multiple compression. History · SEC
ANET · Arista Networks
Exchange/risk: NYSE; large-cap high-beta networking. Classification: repair watch. Applicable horizon: day and 1–4 weeks. Direction: uncertain.
Thesis/evidence: +2.68% to $192.84, back above the $192.16 20-day average; scale-out networking remains the thesis. Counterargument: −4.44% over 20 sessions and below $199.59 five-day high; one rebound is not repair. Entry/confirmation: close above $200 with sector breadth and volume. Invalidation/downside: close below $187.80, stronger below $181. Risks: hyperscaler concentration, capex pauses, competition, supply, exports and valuation. History
IONQ · IonQ
Exchange/risk: NYSE; small-cap/pre-profit; extreme acquisition, dilution and technical risk. Classification: stabilization watch only. Applicable horizon: day and 1–4 weeks. Direction: uncertain.
Thesis/evidence: $37.05, −1.20%, below $39.93 20-day average and −20.90% over 20 sessions. No Sep. 15 operating filing changed the case. Counterargument: ecosystem tools and contract headlines can cause sharp squeezes. Entry/confirmation: close above $40, stronger above $44; no anticipation. Invalidation/downside: close below $35. Risks: roadmap, bookings quality, acquired SkyWater integration, cash burn, warrants/dilution, gaps and liquidity. Borrow terms unknown. SEC · History
ALT · Altimmune
Exchange/risk: Nasdaq; small-cap clinical biotech, pre-commercial, extreme binary/dilution risk. Classification: clinical/regulatory watch. Applicable horizon: 1–4 weeks and 3–12+ months only after FDA-path clarity. Direction: uncertain.
Thesis/evidence: RECLAIM met its Phase 2 primary and important secondary endpoints; $3.23 remains +7.67% over 20 sessions despite Tuesday −2.12%. Counterargument: N=100, GI adverse events and 10% drug-related discontinuation; Phase 3 design, competition and financing remain open. Entry/confirmation: FDA EOP2 clarity plus close above $3.55. Invalidation/downside: unfavorable Phase 3 burden, delay/financing or close below $2.90. Cash/runway: latest 10-Q must be reviewed before sizing; no runway estimate asserted. Risks: endpoints, safety, regulatory path, approved/off-label AUD competition, manufacturing and dilution. Release · 10-Q
Scores are 0–100. Higher Risk means riskier. Thesis Confidence grades evidence quality—not guaranteed probability of profit. Entries are conditional confirmation rules, not guaranteed fills.
Changes versus the 2026-09-15 report
- Regime improves one notch to neutral/risk-high: oil and yields eased overnight and futures rose, but today's FOMC/SEP prevents a risk-on designation.
- ORCL trigger confirmed again: Tuesday's $140.35 close broke the prior $141 rule; it remains bearish #1, but entries now require a failed reclaim or fresh sub-$139 break to avoid chasing.
- VRT failed to stabilize: another close at a five-day low keeps it tactical avoid. COHR bounced 1.75% and is removed from the ranked bearish list rather than chased.
- AMD/ANET showed relative strength: both rose more than 2%; AMD joins the watchlist, but neither is promoted to bullish before sector breadth and Fed confirmation.
- Quantum deteriorated: all four tracked names fell and 20-session losses remain double-digit; IONQ stays watch-only with a higher confirmation threshold.
- VKTX broke risk control: $29.95 closed below the prior $31.39 invalidation on 1.57× volume; it moves from event watch to avoid-until-data/repair.
- New macro evidence: UK August CPI accelerated to 3.1%; U.S. import/export prices and the Fed decision were not yet available at cutoff.
Important catalysts · next 7–30 days
Sep. 16 · 14:30 CEST — U.S. import/export prices
External-inflation input; unavailable at 08:33 CEST. BLS
External-inflation input; unavailable at 08:33 CEST. BLS
Sep. 16 · 20:00/20:30 CEST — FOMC decision/SEP and press conference
Quarter-point hike widely priced; path, dots and reaction function are the larger duration-equity catalysts. Federal Reserve · CME
Quarter-point hike widely priced; path, dots and reaction function are the larger duration-equity catalysts. Federal Reserve · CME
Sep. 18 — BOJ decision
CNBC survey: 89% expect +25 bp to 1.25%; watch yen/JGB spillover. CNBC
CNBC survey: 89% expect +25 bp to 1.25%; watch yen/JGB spillover. CNBC
Sep. 18 — U.S. industrial production
Growth/capacity evidence at 09:15 ET. Fed
Growth/capacity evidence at 09:15 ET. Fed
Sep. 24 — SCOOS / U.S. international transactions
Dealer-financing and capital-flow evidence. Fed · BEA
Dealer-financing and capital-flow evidence. Fed · BEA
Sep. 28–Oct. 2 — EASD 2026
Obesity/diabetes evidence flow; unpublished outcomes are not assumed. Novo/EASD
Obesity/diabetes evidence flow; unpublished outcomes are not assumed. Novo/EASD
Sep. 29 — August JOLTS
Labor-demand input for the post-Fed path. BLS
Labor-demand input for the post-Fed path. BLS
Sep. 29/30 — IONQ warrant trading cessation / expiry
Capital-structure flows may distort price; borrow conditions are not asserted. SEC
Capital-structure flows may distort price; borrow conditions are not asserted. SEC
By Sep. 30, undated — VKTX Phase 1 maintenance data
Issuer-guided Q3 window; exploratory weight durability plus safety/tolerability/PK. Viking
Issuer-guided Q3 window; exploratory weight durability plus safety/tolerability/PK. Viking
Sep. 30 — U.S. GDP third estimate; income/outlays
Growth, profits and inflation evidence. BEA
Growth, profits and inflation evidence. BEA
By mid-October, undated — ALT FDA-path watch
Company plans an EOP2 request for RECLAIM; no meeting date is published. Altimmune
Company plans an EOP2 request for RECLAIM; no meeting date is published. Altimmune
Bottom line by horizon
Day trade
Stance: wait for U.S. price discovery; do not extrapolate a 02:30 ET futures bounce through the Fed. Only act on failed reclaims/breakouts with breadth and volume.
Biggest risk: a Fed/oil headline gap. Invalidation: sustained 10Y below 4.90%, WTI below $100 and SMH/ORCL repair would neutralize the bearish setups; renewed 10Y >5.04% and WTI >$106 would negate rebound longs.
1–4 week swing
Stance: smaller exposure through Fed and BOJ; prefer cash-generative leaders after technical repair. Avoid pre-profit quantum and pre-data biotech anticipation.
Biggest risk: oil-driven inflation and synchronized tightening. Invalidation: broad-index higher highs with falling yields/oil and equal-weight/semiconductor breadth would shift the regime toward risk-on.
3–12+ month investment
Stance: AI infrastructure demand remains plausible but must convert into durable margins/FCF. Quantum needs independent utility/economics; peptide assets need complete efficacy, safety, regulatory and runway analysis.
Biggest risk: cost of capital, concentration/circular financing, dilution and technical/clinical failure. Invalidation: sustained order/cash deterioration or failed clinical/technical milestones—not daily price noise.
Data quality, sources and limitations
- Research performed: more than five meaningful live retrievals covered CNBC current market/news pages and browser quotes; Yahoo chart APIs; official Treasury XML; Federal Reserve/BLS/ONS calendars/releases; SEC submissions; Nvidia/Viking/Altimmune IR; and ClinicalTrials.gov.
- Timestamps: U.S. cash/theme prices are Sep. 15 closes. Futures, commodities, FX and Asia were retrieved around 08:30–08:33 CEST. Hong Kong/Shanghai were open. Europe values are Sep. 15 closes because Wednesday cash markets were pre-open. Official Treasury curve is Sep. 15; CNBC rates are overnight Sep. 16.
- Cross-checks: U.S./Asia index moves and futures were checked against CNBC plus Yahoo charts; yields against Treasury and CNBC; UK CPI against ONS/CNBC; filings against SEC; biotech designs/results against issuer releases and ClinicalTrials.gov.
- Session-basis limitation: Yahoo daily futures bars showed larger percentage moves than CNBC's contemporaneous contract snapshot because baselines/session conventions differ. The dashboard uses Yahoo outright levels and CNBC's stated +0.22%/+0.30% futures changes rather than synthesizing them.
- Source failures: Yahoo's multi-symbol quote endpoint returned HTTP 429, so individual chart endpoints were used successfully. CNBC Europe/oil standalone extraction hit tunnel/rate limits, but the accessible current CNBC live blog and markets page contained the relevant figures. Nvidia/Vertiv list-page URLs returned 404 and IonQ IR was blocked by an internal-network rule; SEC submissions and direct issuer releases were successful alternatives. No data is declared unavailable.
- Discipline: no fresh analyst rating, consensus earnings estimate, premarket single-stock price, FDA outcome, borrow availability/fee or unpublished trial result is asserted. Technical averages/volume ratios were calculated from retrieved daily bars; scores are judgment, not market data.